A5051929582- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Dermatology and Skin Diseases
- Vaccine Coverage and Hesitancy
- Immunotherapy and Immune Responses
- Inflammatory Biomarkers in Disease Prognosis
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Allergic Rhinitis and Sensitization
- Eosinophilic Esophagitis
- IL-33, ST2, and ILC Pathways
- Asthma and respiratory diseases
- Transgenic Plants and Applications
- Adrenal Hormones and Disorders
- Biomarkers in Disease Mechanisms
- Rheumatoid Arthritis Research and Therapies
Eli Lilly (United States)
2018-2023
As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, availability demand for monoclonal antibodies prevention treatment of severe acute respiratory syndrome 2 (SARS-CoV-2) infection are also accelerating. This longitudinal serological study evaluated magnitude potency endogenous antibody response to COVID-19 vaccination in participants who first received a study. Over course 6 months, serum samples were collected from population nursing home residents...
IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13.We undertook studies to compare vitro binding affinities cell-based functional activities of lebrikizumab, cendakimab.Lebrikizumab bound with higher affinity (as determined using surface plasma resonance) slower off-rate. It was more potent neutralizing IL-13-induced...
Background Neutralizing monoclonal antibodies (mAbs) to SARS-CoV-2 are clinically efficacious when administered early, decreasing hospitalization and mortality in patients with mild or moderate COVID-19. We investigated the effects of receiving mAbs (bamlanivimab alone bamlanivimab etesevimab together) after infection on endogenous immune response. Methods Longitudinal serum samples were collected from COVID-19 BLAZE-1 trial who received placebo (n=153), [700 mg (n=100), 2800 (n=106), 7000...
Breaking tolerance is a key event leading to autoimmunity, but the exact mechanisms responsible for this remain uncertain. Here we show that alarmin IL-33 able drive generation of autoantibodies through induction B cell survival factor BAFF. A temporary, short-term increase in results primary (IgM) response self-antigens. This transient DNA-specific autoantibody was dependent on Notably, radiation resistant cells and not myeloid cells, such as neutrophils or dendritic were major source BAFF...
Abstract As the COVID-19 pandemic evolves, and vaccine rollout progresses, availability demand for monoclonal antibodies prevention treatment of SARS-CoV-2 infection are also accelerating. This longitudinal serological study evaluated magnitude potency endogenous antibody response to vaccination in participants who first received a study. Over course six months, serum samples were collected from population (nursing home residents staff) enrolled BLAZE-2 clinical trial had either bamlanivimab...
Abstract This first of its kind study provides objective context to the potential mechanism action corticosteroid use in COVID-19 patients from 3 separate European medical centers by connecting inflammatory biomarkers IgG levels for SARS-CoV-2 spike protein antigens and neutralization ACE2 binding within infected individuals. CXCL9 is described herein as an important biomarker disease severity with serology response profiles corticosteroid-treated patients.